Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants.
about
EthnopsychopharmacologyPharmacogenetics and psychopharmacotherapy.CYP2D6 in the metabolism of opioids for mild to moderate pain.Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system.Enantiomeric antidepressant drugs should be considered on individual merit.A review and assessment of potential sources of ethnic differences in drug responsiveness.Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms.CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype.The pharmacokinetics of codeine and its metabolites in Blacks with sickle cell disease.Impact of CYP2D6 polymorphism on tamoxifen therapy: where are we?Cytochrome P450 pharmacogenetics in African populations.Priority pharmacogenetics for the African continent: focus on CYP450.Cytochrome P450 pharmacogenetics in African populations: implications for public health.Molecular diversity at the CYP2D6 locus in healthy and schizophrenic southern Brazilians.Effective therapeutic dosage of antipsychotic medications in patients with psychotic symptoms: Is there a racial difference?Phenotyping and genotyping of CYP2C19 using comparative metabolism of proguanil in sickle-cell disease patients and healthy controls in Nigeria.Establishment of a biobank and pharmacogenetics database of African populations.CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico.
P2860
Q28301029-05E1180D-F65B-45F7-8FC4-D05D8F83369BQ33962212-C395C1A8-638C-49F5-B324-043862014501Q34178485-5CF8AB35-7879-40C3-8A39-57115B43CA4DQ34466778-41372314-7318-4A4C-95F9-C18ADCD70248Q34982628-54EAAE6E-A2CC-4597-AFB3-CB656D83C985Q35217493-F5B850F2-C46B-4C32-8C53-7F74D628A82FQ35876954-C6DCA711-1484-4C1A-8489-34463D479987Q36053309-A34B3402-538A-4314-B141-A5531CD7F940Q37178666-169D6EEB-7EBB-43EE-A5E6-4DA8CEDF70F1Q38017920-7F59E28D-B866-4069-81DE-C9C2578A4295Q38099372-38B8DD88-2DBA-48C1-8D60-C2F4FFD92560Q38188600-D4994FC4-35FE-40A3-821A-0320DF58D7E8Q38192688-0871CDB8-5D0E-4EAB-8909-82C451A1391EQ39946483-9C517AE0-1FB3-4A8E-9D5D-37FBE826A8CCQ40058051-1316EC8B-DB64-4624-BF4D-21BBFC67C76AQ41265929-4695EB1F-00D6-47B8-AFE4-5964FE3CE70BQ46573709-0B2BD6E7-719B-4303-99DB-C8FF72A6B2A6Q54605695-C0834627-E45F-43B5-BA4C-EBF3D0720BEE
P2860
Genetic polymorphism of drug metabolising enzymes in African populations: implications for the use of neuroleptics and antidepressants.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Genetic polymorphism of drug m ...... roleptics and antidepressants.
@en
type
label
Genetic polymorphism of drug m ...... roleptics and antidepressants.
@en
prefLabel
Genetic polymorphism of drug m ...... roleptics and antidepressants.
@en
P1476
Genetic polymorphism of drug m ...... roleptics and antidepressants.
@en
P2093
C M Masimirembwa
J A Hasler
P304
P356
10.1016/S0361-9230(97)00307-9
P577
1997-01-01T00:00:00Z